Press Releases

2018.02.23 R&D PDF (181KB)
Daiichi Sankyo Initiates Phase 1 Study of DS-1062 in Patients with Advanced Non-Small Cell Lung Cancer
2018.02.23 Corporate PDF (117KB)
Daiichi Sankyo Appoints New Group Corporate Officers
2018.02.23 Corporate PDF (88KB)
Daiichi Sankyo Announces Organizational Restructuring Effective as of April 1, 2018
2018.02.22 Products PDF (111KB)
Daiichi Sankyo Submits Application for Additional Indication and Dosage for DiagnogreenⓇ for Injection 25 mg in Japan
2018.02.21 Corporate PDF (135KB)
Daiichi Sankyo Selected for 2018 Certified Health and Productivity Management Organization (White 500)
2018.02.15 R&D PDF (109KB)
Daiichi Sankyo Submits Marketing Application for Mirogabalin in Japan
2018.02.07 R&D PDF (182KB)
Daiichi Sankyo Initiates Phase 1 Study of U3-1402 in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
2018.02.02 CSR PDF (125KB)
Daiichi Sankyo Selected for Silver Class of RobecoSAM Sustainability Award 2018
2018.02.02 R&D PDF (92KB)
Daiichi Sankyo Announces Update on Amgen Inc.’s Phase 3 Clinical Trial Evaluating Denosumab as Adjuvant Breast Cancer Treatment
2018.02.01 Corporate PDF (90KB)
Daiichi Sankyo Announces Status Relating to Acquisition of Own Shares
2018.01.31 Corporate PDF (90KB)
Daiichi Sankyo to Record Loss on Valuation of Kitasato Daiichi Sankyo Vaccine Co., Ltd. Shares in Non-consolidated Accounts
2018.01.19 Products PDF (132KB)
Nexium® 10 mg and 20 mg Capsules received additional approval of paediatric dosage and administration, and marketing approval of Nexium® 10 mg and 20 mg Granules for Suspension, Sachet in Japan
2018.01.19 R&D PDF (272KB)
Daiichi Sankyo Presents Updated Data for DS-8201 in Patients with HER2-Expressing Gastric Cancer at ASCO 2018 Gastrointestinal Cancers Symposium
2018.01.05 Corporate PDF (90KB)
Daiichi Sankyo Announces Status Relating to Acquisition of Own Shares

In order to view the PDF files, you need to have the latest version of Adobe Reader installed.